Compare MNSB & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNSB | CNTN |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 178.5M |
| IPO Year | 2017 | 2021 |
| Metric | MNSB | CNTN |
|---|---|---|
| Price | $23.95 | $1.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.3K | ★ 847.8K |
| Earning Date | 10-26-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 210.00 | 88.10 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $135,615,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.86 | $1.75 |
| 52 Week High | $25.87 | $5.27 |
| Indicator | MNSB | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 41.14 | 32.31 |
| Support Level | $24.24 | N/A |
| Resistance Level | $25.29 | $2.40 |
| Average True Range (ATR) | 0.53 | 0.15 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 15.82 | 5.46 |
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.